Sign in Subscribe
Cancer research

Exceptional Long-term Response to Immunotherapy in Lung Cancer Treatment

Strategic Insights

— 1 min read

A new study published in the Journal of Investigative Medicine High Impact Case Reports has highlighted the exceptional long-term response of an African American man with mutated metastatic lung adenocarcinoma to immunotherapy treatment. The patient's response, which lasted over two years, has been attributed to his STK11/TP53 co-mutation, high tumor mutation burden, and high PD-L1 expression. This study has shed light on the importance of incorporating genetic ancestry differences in the treatment of lung cancer, ensuring equitable and optimal treatment for all patients.

Key Takeaways:

  • A 68-year-old African American man with stage IIIB lung adenocarcinoma demonstrated an exceptional and sustained response to immunotherapy for over two years, despite having STK11 mutations associated with immunotherapy resistance.
  • The patient's STK11/TP53 co-mutation, high tumor mutation burden, and high PD-L1 expression may have contributed to his continued responsiveness to immunotherapy.
  • This study highlights the importance of incorporating genetic ancestry differences in the treatment of lung cancer, ensuring equitable and optimal treatment for all patients.
  • Specific mutations and co-mutations may help explain individual patient responses to immunotherapy.
  • The patient's improved outcome after immunotherapy treatment has significant implications for the treatment of advanced and resectable lung cancer.

Statistics:

  • The patient was 68 years old at the time of treatment.
  • The patient's lung adenocarcinoma was stage IIIB.
  • The patient had a high tumor mutation burden (19.0 mutations/Mb) and high PD-L1 22c3 expression (TPS 70%, 2+ intensity).
  • The patient's response to immunotherapy lasted over two years.
  • The study's findings may help ensure the equitable and optimal treatment of all patients with lung cancers.

Sources:

  • Zhou, Yin, et al. "Exceptional Long-term Response to Immunotherapy in an African American Man With -Mutated Metastatic Lung Adenocarcinoma." Journal of Investigative Medicine High Impact Case Reports, vol. 13, 2025, https://doi.org/10.1177/23247096251346830.
  • NewsRx. "New Data from East Carolina University Illuminate Research in Lung Cancer (Exceptional Long-term Response to Immunotherapy in an African American Man With -Mutated Metastatic Lung Adenocarcinoma)." Immunotherapy Weekly, June 18, 2025, p 2471.

Read more